CSPC Innovation Pharmaceutical (300765) Q3 2024 earnings summary

Executive summary

• Revenue for the first nine months of 2024 was ¥1,478.92 million, down 23.66% year-over-year due to lower caffeine prices and decreased health food sales.

• Net profit attributable to shareholders was ¥139.33 million, a 63.50% decrease year-over-year, impacted by increased R&D expenses and market challenges.

• R&D expenses for subsidiary Jushi Biotech surged, with five products entering clinical trials and key products accelerating enrollment.

Financial highlights

• Operating income for the first nine months was ¥1,478.92 million, down from ¥1,937.21 million year-over-year.

• Net profit attributable to shareholders was ¥139.33 million, compared to ¥381.76 million in the same period last year.

• Basic and diluted EPS for the period were ¥0.0995, down from ¥0.2738 year-over-year.

• Gross margin declined as revenue and cost reductions did not offset the impact of lower product prices.

• Net cash flow from operating activities was -¥955.58 million, a significant decrease from -¥6.99 million year-over-year.

Outlook and guidance

• Management highlights ongoing R&D investment and product pipeline progress but notes continued pressure from raw material price declines and market headwinds.